Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — Q4 2024 Earnings Presentation
9 slides from Crinetics Pharmaceuticals's earnings presentation, Feb 27, 2025
Slide 1: Fourth Quarter and Full Year 2024 Financial Results and Business Update
® February 27, 2025 Fourth Quarter and Full Year 2024 Financial Results and Business Update
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Su
Slide 3: Demonstrated Execution in 2024 Set Strong Foundation for Transformational 2025
Demonstrated Execution in 2024 Set Strong Foundation for Transformational 2025 2024 2025 Strengthened Balance Sheet to ~$1.4B Grow Commercial Engine Cash and Investments* Execute on Clinical Objectives PDUFA Date September 25, 2025 First NDA Accepted for Acromegaly EU Regulatory Filing Expected 1H20
Slide 4: We Aspire to Make Paltusotine the Standard of Care in Acromegaly
We Aspire to Make Paltusotine the Standard of Care in Acromegaly and Become the Market Leader SHIFT THE MINDSET ACTIVATE WIN ON EFFICACY A D OPT ENSURE ACCESS A C C ESS DRIVE ADHERENCE THROUGH SUPPORT A D H ERE 4
Slide 5: Continued Value Creation with Deep Pipeline of Transformative Drug Candidates
Continued Value Creation with Deep Pipeline of Transformative Drug Candidates Program Discovery IND-Enabling Phase 1 Phase 2 Phase 3 Registrational Milestones / Partner Acromegaly PDUFA Date (September 2025) Paltusotine (SST2 agonist) Carcinoid syndrome Phase 3 FPI (2Q 2025) Congenital adrenal hyper
Slide 6: Four INDs Expected in 2025 Driving Next Wave of Innovation
Four INDs Expected in 2025 Driving Next Wave of Innovation Indication Neuroendocrine Hyperparathyroidism Graves / TED ADPKD¹ Tumors (NETs) Target SST2+ NDC PTH antagonist TSH antagonist SST3 agonist (CRN09682) 200K incident 3M+ patients Approximate 140K patients with 300K+ patients with Graves, US P
Slide 7: Financials
Financials Three months ended December 31, Full Year (in millions) 2024 2023 2024 2023 Revenues $ 0.0 $ 0.0 $ 1.0 $ 4.0 R&D Expenses (66.6) (45.6) (240.2) (168.5) G&A Expenses (28.2) (17.1) (99.7) (58.1) Net Loss $(80.6) $(60.1) $(298.4) $(214.5) Cash and equivalents totaled $1.4 billion as of Dec
Slide 8: Exploring New Frontiers to Expand Patient Reach
Exploring New Frontiers to Expand Patient Reach > 1M > 100K Preclinical > 10K IND Enabling Obesity Clinical-Stage Approximate US Patients Graves’ Disease Other GPCR- driven Oncology Thyroid Ophthalmopathy Acromegaly Hyperparathyroidism Polycystic Kidney Disease Cushing’s Disease Carcinoid Syndrome N
Slide 9: Thank You
| THANK YOU armaceuticals
Crinetics Pharmaceuticals — Q4 2024 Earnings Presentation on 6ix